Artica Therapeutics - About the company
Artica Therapeutics is a seed company based in Leiden (Netherlands), founded in 2020 by Tjeerd Barf, Ad Ijzerman and Arwin Ridder. It operates as a Developer of small molecule therapeutics for immunological disorders. Artica Therapeutics has raised $12.7M in funding from Thuja Capital and Seroba Life Sciences. The company has 434 active competitors, including 137 funded and 118 that have exited. Its top competitors include companies like BeiGene, Biogen and argenx.
Company Details
Developer of small molecule therapeutics for immunological disorders. It offers covalent drugs based on covalent binding technology as well as in label-free cellular-based screening approaches for the treatment of inflammatory and autoimmune indications.
- Website
- www.artica-tx.com/
- Email ID
- *****@artica-tx.com
Key Metrics
Founded Year
2020
Location
Leiden, Netherlands
Stage
Seed
Total Funding
$12.7M in 1 round
Latest Funding Round
Investors
Ranked
201st among 434 active competitors
Employee Count
19 as on Aug 31, 2026
Sign up to download Artica Therapeutics' company profile
Artica Therapeutics's funding and investors
Artica Therapeutics has raised a total funding of $12.7M over 1 round. Its latest funding round was a Seed round on Nov 02, 2023 for $*****. 4 investors participated in its latest round. Artica Therapeutics has 4 institutional investors.
Here is the list of recent funding rounds of Artica Therapeutics:
Date of Funding | Funding Amount | Round Name | Post-Money Valuation | Revenue Multiple | Lead Investors | Other Investors |
|---|---|---|---|---|---|---|
Nov 02, 2023 | 6739504 | Seed | 5122739 | 4126531 | 6270273 | 6079398 |
Access funding benchmarks and valuations. Sign up today!View details of Artica Therapeutics's funding rounds and investors
Artica Therapeutics' founders and board of directors
Founder? Claim ProfileThe founders of Artica Therapeutics are Tjeerd Barf, Ad Ijzerman and Arwin Ridder. Tjeerd Barf is the CEO of Artica Therapeutics.
Here are the details of Artica Therapeutics' key team members:
- Tjeerd Barf: CEO and Founder of Artica Therapeutics and founder of 1 other company.
- Ad Ijzerman: Co-Founder of Artica Therapeutics. Contact Info: 1 email address
- Arwin Ridder: Co-Founder of Artica Therapeutics. Contact Info: 1 email address
View details of Artica Therapeutics's Founder profiles and Board Members
Artica Therapeutics' employee count trend
Artica Therapeutics has 19 employees as of Aug 26. Here is Artica Therapeutics's employee count trend over the years:
Uncover Artica Therapeutics' growth story! Sign up today!
Access Tracxn on any website
Install Tracxn ExtensionOur Google Chrome extension lets you view company details while browsing their websites
Artica Therapeutics's Competitors and alternates
Top competitors of Artica Therapeutics include BeiGene, Biogen and argenx. Here is the list of Top 10 competitors of Artica Therapeutics, ranked by Tracxn score:
Get insights and benchmarks for competitors of 2M+ companies! Sign up today!
Rank | Company Details | Short Description | Total Funding | Investors | Tracxn Score |
|---|---|---|---|---|---|
1st |  BeiGene 2010, Cambridge (United States), Public | Developer of targeted and immune-oncology drugs against cancer | $172M | 81/100 | |
2nd |  Biogen 1978, Cambridge (United States), Public | Developer of therapies for neurodegenerative and immunology disorders | $80M | 78/100 | |
3rd | Developer of antibody-based drugs to treat autoimmune diseases and cancer | $61.9M | 75/100 | ||
4th | C4 Therapeutics 2016, Cambridge (United States), Public | Developer of small molecule drugs for treating cancer | $223M | 71/100 | |
5th |  Abcellera Biologics 2012, Vancouver (Canada), Public | AI-enabled platform for antibodies discovery | $115M | 71/100 | |
6th | Developer of immunotherapeutics for the treatment of cancer and other diseases | $861M | 69/100 | ||
7th |  Nimbus Therapeutics 2009, Cambridge (United States), Series F | Developer of targeted therapeutics for cancer, metabolic and inflammatory diseases | $637M | 69/100 | |
8th | ADMA Biologics 2005, Ramsey (United States), Public | Biopharmaceutical company innovating plasma-derived therapeutics for immune deficiencies and infectious diseases | $17.6M | 69/100 | |
9th | DBV Technologies 2002, Bagneux (France), Public | Developer of products for the treatment of various kinds of food allergies | $68.9M | 68/100 | |
10th | Theravance Biopharma 2001, Francisco (United States), Public | Developer of therapeutics for inflammatory and immunological diseases | - | 68/100 | |
201st |  Artica Therapeutics 2020, Leiden (Netherlands), Seed | Developer of small molecule therapeutics for immunological disorders | $12.7M | 34/100 |
Get insights and benchmarks for competitors of 2M+ companies! Sign up today!Looking for more details on Artica Therapeutics's competitors? Click here to see the top ones
Artica Therapeutics's Investments and acquisitions
Artica Therapeutics has made no investments or acquisitions yet.
Reports related to Artica Therapeutics
Here is the latest report on Artica Therapeutics's sector:
News related to Artica Therapeutics
•
Dutch-based Artica Therapeutics bags €12M to help patients suffering from autoimmune and inflammatory disordersSilicon Canals•Nov 03, 2023•Artica Therapeutics, Thuja Capital, Seroba Lifesciences, InnovationQuarter and 1 other
Get curated news about company updates, funding rounds, M&A deals and others. Sign up today!Are you a Founder ?
FAQs about Artica Therapeutics
Explore our recently published companies
- Hallway Talk - Denver based, 2014 founded, Unfunded company
- Shalom Hills - Gurugram based, 2004 founded, Unfunded company
- The Space Station - Unfunded company
- Ralph van Roosmalen - Unfunded company
- Universidad Virtual Hispanica de Mexico - Mexico based, Unfunded company
- BRANDOW'S FEED & SEED - Oneonta based, 2005 founded, Unfunded company
